Turk J Immunol. 2020; 8(3): 135-143 | DOI: 10.25002/tji.2020.1347

Frequency of Autoantibodies Against 3-Deoxyglucosone H1 Protein in Type 2 Diabetes

Jalaluddin M. Ashraf¹, Shahnawaz Rehman^3
1Department of MLT, Applied Medical Sciences, Jazan university, Jazan, Saudi Arabia
²Medical Research Centre, Jazan University, Jizan, Saudi Arabia
³Integral University, Biosciences, Lucknow, India

Introduction: Advanced glycation end-products (AGEs) are contributing factors to diabetes complications. The
antigenic nature of AGEs established the theory of incessant accumulation of AGEs can incite an autoimmune response
in a diabetic patient. Glycating agents like 3-deoxyglucosone are increased in diabetic patients, leading to the high
formation of AGEs aggravating the pathophysiological conditions in diabetes. We aimed to study the immunogenicity
of glycated histone H1 protein and AGEs (N-carboxymethyl-lysine and pentosidine) as well as detection of
autoantibodies in the sera of type 2 diabetic subjects.
Materials and Methods: Female rabbits were injected with native H1 and glycated-H1 to discern its immunogenicity.
Diabetic subjects’ sera were also scanned for the detection of autoantibodies against glycated-H1 and AGEs using
immunochemical assay technique.
Results: Glycated-H1 was highly immunogenic, unlike the native analog. Diabetic sera showed 48% (72 of 150
samples) significantly strong binding with glycated-H1, further sera also showed 40% (60 of 150 samples), and 36%
(54 of 150 samples) strong binding with CML, and pentosidine, respectively.
Conclusion: The findings support modified H1 as well AGEs are highly immunogenic in nature. The presence of
autoantibodies against glycated-H1 and AGEs may be utilized in the assessment of diabetes or its complications.

Keywords: Baðýþýklanabilirlik, 3-deoksiglukozon, ileri glikasyon son-ürünleri, diabet

---

Tip 2 Diabette 3-Deoksiglukazon-H1 Proteinine Karþý Otoantikorlarýn Sýklýðý

Jalaluddin M. Ashraf¹, Shahnawaz Rehman^3
1
2
3

Giriþ: Ýleri-glikasyonlanmýþ son ürün (ÝGS)’ler diabette komplikasyonlarýn geliþimine katkýda bulunur. ÝGS’lerin
antijenik özellikte olmalarý, diabet olan hastalarda otoimmüniteyi tetikleyebileceklerini düþündürtmektedir.
3-deoksiglikazon gibi glikalleyici ajanlar, diabetik hastalarda daha fazla ÝGS birikimine ve böylece bazý patofizyolojik
durumlara yol açýyor olabilir. Bu çalýþmada glikallenmiþ H1 histon proteini ve ÝGS’lerin (pentosidin ve N-karboksimetillizin)
baðýþýklýðý uyarma özelliðini ve tip 2 diabeti olan hastalarda otoantikorlarýn çalýþýlmasý planlanmýþtýr.
Gereçler ve Yöntemler: Diþi tavþanlara baðýþýkl yanýtýný uyarmak için doðal ve glikasyon olmuþ H1 injekte edildi.
Diabet olan deneklerin serumlarýnda immünohistokimyasal yöntem ile ve glikasyon olmuþ H1’e ÝGS’ye karþý
otoantikorlar araþtýrýldý.
Bulgular: Glikasyonlu-H1, doðal H1’in tersine baðýþýklýðý çok iyi uyarýr bulundu. Dibetli deneklerden alýnan
serumlarýn %48’inde (150 örneðin 72’sinde) glikasyonlu-H1’e karþý antikor bulunur iken, ÝGS’ye karþý %40 (150
örneðin 40’ýnda), pentosisidine karþý ise %36 hayvanda antikor saptandý.
Sonuçlar: Bulgulara göre, deðiþtirilmiþ H1 ve ÝGS doðal olarak baðýþýklýðý oldukça kuvvetli bir þekilde uyarmaktadýr.
Glikasyonlu-H1 ve ÝGS’ye karþý oluþan otoantikorlar, diabet ya da komplikasyonlarýnýn saptanmasýnda kullanýlabilir.

Anahtar Kelimeler: immunogenicity, 3-deoxyglucosone, advanced glycation end-products, diabetes

---

CITE